Last reviewed · How we verify
BRM421
At a glance
| Generic name | BRM421 |
|---|---|
| Sponsor | BRIM Biotechnology Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
- A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease (PHASE2)
- Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects. (PHASE3)
- Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment (PHASE2, PHASE3)
- Safety and Efficacy of BRM421 for Dry Eye Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |